Inovio Shares Rise Following Positive Phase 3 Trial Results from Partner ApolloBio
Shares of Inovio Pharmaceuticals (INO) increased after its partner in China, ApolloBio, reported successful results from a late-stage trial for the DNA vaccine VGX-3100 against cervical dysplasia. The topline data showed positive outcomes, contributing to an upward movement in INO's stock price.
Tickers: $INO